Gordian Capital Singapore Pte Ltd Purchases 470 Shares of Merus (NASDAQ:MRUS)

Gordian Capital Singapore Pte Ltd boosted its position in shares of Merus (NASDAQ:MRUS) by 10.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,000 shares of the biotechnology company’s stock after buying an additional 470 shares during the period. Gordian Capital Singapore Pte Ltd’s holdings in Merus were worth $250,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. nVerses Capital LLC boosted its stake in Merus by 750.0% during the third quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 1,500 shares during the last quarter. US Bancorp DE bought a new position in Merus during the third quarter valued at approximately $103,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Merus by 24.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock valued at $118,000 after buying an additional 489 shares during the last quarter. MML Investors Services LLC bought a new stake in shares of Merus in the 3rd quarter valued at approximately $206,000. Finally, Farallon Capital Management LLC bought a new stake in shares of Merus in the 2nd quarter valued at approximately $237,000. 96.14% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $85.00 price objective on shares of Merus in a research note on Monday, December 2nd. The Goldman Sachs Group assumed coverage on Merus in a research note on Thursday, November 21st. They issued a “buy” rating and a $73.00 price objective for the company. UBS Group assumed coverage on Merus in a research note on Thursday, October 24th. They issued a “buy” rating and a $72.00 price objective for the company. Guggenheim reaffirmed a “buy” rating and issued a $109.00 price objective (down from $111.00) on shares of Merus in a research note on Tuesday, December 3rd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $85.00 price objective on shares of Merus in a research note on Monday, December 2nd. One equities research analyst has rated the stock with a sell rating, twelve have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Merus currently has an average rating of “Buy” and an average target price of $85.27.

Merus Trading Up 1.8 %

Shares of NASDAQ MRUS opened at $44.65 on Monday. The business’s 50 day moving average price is $49.73 and its 200-day moving average price is $51.92. Merus has a fifty-two week low of $22.27 and a fifty-two week high of $61.61.

Merus (NASDAQ:MRUS) last released its quarterly earnings data on Thursday, October 31st. The biotechnology company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.05). The firm had revenue of $11.77 million for the quarter, compared to analysts’ expectations of $9.11 million. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. Analysts forecast that Merus will post -3.89 earnings per share for the current year.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.